International Journal of Clinical Case Reports 2024, Vol.14, No.5, 290-298 http://medscipublisher.com/index.php/ijccr 291 significant side effects and suboptimal survival rates. By introducing advanced techniques such as stereotactic body radiotherapy (SBRT), intensity-modulated radiotherapy (IMRT), and proton beam therapy (PBT), this study aims to achieve more precise tumor targeting while reducing radiation toxicity, thereby improving local control and survival rates. Additionally, the integration of advanced imaging technologies, artificial intelligence, and personalized treatment approaches further enhances the precision and effectiveness of radiotherapy, with the ultimate goal of improving treatment outcomes for lung cancer patients. This study holds theoretical significance, providing a foundation for the future development of radiotherapy for lung cancer, and it also has important clinical implications, offering optimized treatment strategies to improve overall prognosis for lung cancer patients. 2 Advances in Radiotherapy Techniques for Lung Cancer 2.1 Stereotactic body radiotherapy (SBRT) Stereotactic body radiotherapy (SBRT) has revolutionized the treatment of early-stage non-small cell lung cancer (NSCLC), particularly for medically inoperable patients. This technique delivers highly focused, high-dose radiation to tumor sites while minimizing exposure to surrounding healthy tissues. SBRT's precise targeting has significantly improved local control rates and reduced treatment-related toxicities, making it an attractive option for early-stage lung cancer patients. Recent studies have shown that SBRT offers comparable outcomes to surgery, especially in elderly patients or those with comorbidities (Diwanji et al., 2017). SBRT also offers a non-invasive alternative to patients who are unfit for surgery, demonstrating excellent control of local tumors with a favorable toxicity profile (Kreinbrink et al., 2017). 2.2 Intensity-modulated radiotherapy (IMRT) Intensity-modulated radiotherapy (IMRT) is an advanced radiotherapy technique that allows for the precise modulation of radiation beams to conform to the shape of the tumor. This results in higher radiation doses to the tumor while sparing adjacent normal tissues, such as the lungs and heart. IMRT has demonstrated efficacy in treating both early-stage and locally advanced NSCLC by reducing the risk of radiation-induced toxicities while maintaining high local control rates. Furthermore, IMRT is particularly beneficial for patients with complex tumor geometries or those with tumors near critical structures like the heart and spine (Diwanji et al., 2017). Recent innovations, such as volumetric-modulated arc therapy (VMAT), have further enhanced the precision and delivery speed of IMRT, making it a cornerstone in modern radiotherapy for lung cancer . 2.3 Proton and heavy ion therapy Proton therapy, with its unique Bragg peak phenomenon, delivers radiation more precisely to the tumor while minimizing damage to surrounding tissues. This makes it an ideal choice for treating lung cancers located near critical structures, such as the heart and spinal cord. Proton therapy has shown promise in reducing radiation-induced side effects, particularly in patients with locally advanced NSCLC. Furthermore, advanced techniques like pencil beam scanning (PBS) have enhanced the precision of proton therapy, allowing for better dose distribution in complex tumors (Harada and Murayama, 2017). In addition to proton therapy, heavy ion therapy, specifically carbon-ion therapy, offers superior biological effectiveness due to its enhanced ability to kill cancer cells regardless of their oxygen levels or cell cycle phase. Carbon-ion therapy has shown potential for treating radioresistant lung tumors and is under active investigation in clinical trials (Shioyama et al., 2017). 3 Clinical Evidence Supporting Innovative Radiotherapy Approaches 3.1 SBRT in early-stage lung cancer Stereotactic body radiotherapy (SBRT) has demonstrated excellent clinical outcomes in the treatment of early-stage non-small cell lung cancer (NSCLC), particularly for patients who are medically inoperable. Clinical studies show that SBRT achieves high rates of local control, with 5-year local control rates reaching up to 90% (Bae et al., 2022). SBRT has also been shown to offer comparable survival outcomes to surgery, with minimal treatment-related toxicity, making it a standard of care for early-stage, medically inoperable patients (Sun et al., 2020). Additionally, the use of SBRT in elderly patients has been found to be particularly safe and effective, with reduced rates of severe toxicity even in high-risk populations (Cassidy, 2017).
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==